The US pediatric cardiology market size is projected to reach US$ 3,599.40 million by 2031 from US$ 2,541.22 million in 2023. The market is expected to register a CAGR of 4.4% during 2023–2031. Integration of AI and machine learning with pediatric cardiology is likely to bring new trends in the market in the coming years.
Pediatric cardiology is a specialized branch of medicine that focuses on diagnosing, treating, and managing heart conditions in infants, children, and adolescents. This field addresses a range of congenital (present at birth) and acquired heart defects, including conditions such as ventricular septal defects, atrial septal defects, and more complex issues requiring surgical intervention. The US pediatric cardiology market growth is driven by surging incidences of congenital heart defects among Pediatrics and a growing shift toward minimally invasive procedures. Companies are taking numerous initiatives in the field of pediatric cardiology, which are expected to offer significant opportunities for the market growth during the forecast period.
The US houses a few of the major market players, which are focused on research and development of innovative products specifically tailored to cater to the pediatric population. This has led to an increasing number of product launches. Additionally, supportive government policies and initiatives such as awareness campaigns and funding for the development of innovative and novel devices for the treatment of pediatric cardiology disorders are expected to support the US market growth in the coming years.
Chronic congenital heart disease (CCHD), tetralogy of fallot, ventricular septal defect, and atrial septal defect are a few congenital heart diseases (CHDs) that are present from birth. The rising prevalence of maternal health issues, such as diabetes and obesity, has been linked to an increased risk of CHD in newborns. According to the Children's Heart Foundation, CHD is the most common congenital disability in the US. As per the same source, approximately one of every 110 babies is born with a CHD, and each year, ~40,000 babies are born with CHD in the US. In 2023, approximately 20 of every 10,000 babies born in the US were suffering from CCHD, as per the American Academy of Pediatrics. According to the Centers for Disease Control and Prevention (CDC), about 1 in 2,077 babies, that is ~1,768 babies every year in the US, are born with tetralogy of fallot. Furthermore, 13 of every 10,000 babies, about 5,240 babies, in the US each year suffer from atrial septal defects at birth. In addition, about 42 of every 10,000 babies, or ~16,800 babies in the US, are born with ventricular septal defects each year. As survival rates for infants with CHD improve due to advancements in medical care, there is a growing population of children and adolescents requiring ongoing cardiology services. This shift has resulted in a heightened demand for specialized pediatric cardiac care, including diagnostic, surgical, and therapeutic interventions. Thus, the increasing incidence of various congenital heart diseases (CHDs) in the pediatric population fuels the growth of the US pediatric cardiology market.
Companies operating in the US pediatric cardiology market constantly focus on strategic developments such as product approvals, collaborations, funding, agreements, and new product launches, which help them boost their sales, geographic reach, and capacities to cater to a wide customer base. A few strategic initiatives taken by key players operating in the US pediatric cardiology market are mentioned below:
Therefore, strategic initiatives by various companies focusing on the development of pediatric cardiology devices are likely to offer growth opportunities to the US pediatric cardiology market in the coming years.
Key segments that contributed to the derivation of the US pediatric cardiology market analysis are product type, surgical procedures, disease indication, and end user.
The US pediatric cardiology market is a dynamic and rapidly evolving sector, primarily driven by the increasing prevalence of congenital heart defects. According to the Children's Heart Foundation, CHD is the most common congenital disability in the US. As per the same source, approximately one of every 110 babies is born with a CHD, and each year, ~40,000 babies are born with CHD in the US. In 2023, approximately 20 of every 10,000 babies born in the US were suffering from CCHD, as per the American Academy of Pediatrics. This has increased the demand for specialized care and advancements in diagnostic tools, treatments, and technologies tailored specifically for pediatric patients. Key players in the market, such as Abbott Laboratories and Occlutech US LLC, are actively investing in research and development to innovate solutions that enhance patient outcomes, focusing on minimally invasive procedures that reduce recovery times and improve safety.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 2,541.22 Million |
| Market Size by 2031 | US$ 3,599.40 Million |
| Global CAGR (2023 - 2031) | 4.4% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered | US
|
| Market leaders and key company profiles |
The US pediatric cardiology market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the US pediatric cardiology market are listed below:
The "US Pediatric Cardiology Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
The List of Companies - US Pediatric Cardiology Market
The US pediatric cardiology market was valued at US$ 2,541.22 million in 2023.
The US pediatric cardiology market is expected to be valued at US$ 3,599.40 million by 2031.
The US pediatric cardiology market, by product type, is segmented into transcatheter heart valves, occlusion devices, atherectomy devices, catheters, stents, introducer sheaths, and others. The catheters segment held the largest market share in US pediatric cardiology in 2023.
Pediatric cardiology is a specialized branch of medicine that focuses on diagnosing, treating, and managing heart conditions in infants, children, and adolescents. This field addresses a range of congenital (present at birth) and acquired heart defects, including conditions like ventricular septal defects, atrial septal defects, and more complex issues requiring surgical intervention.
The factors driving the growth of the US pediatric cardiology market include surging incidences of congenital heart defects among Pediatrics and growing shift towards minimally invasive procedures. However, the dearth of skilled pediatric cardiologists is hampering the growth of the market.
The US pediatric cardiology market majorly consists of the players, including Abbott Laboratories, Medtronic Plc, Edwards Lifesciences Corp, Terumo Corp, W L Gore and Associates Inc, NuMED, Cordis Corp, Occlutech US LLC, Biotronik SE & Co KG, and RENATA MEDICAL.